Weekly Recap: Ex-China NXP200 rights and Q4 INDs for NXP200 and ciprocopan
Nuvectis Pharma, Inc. (NASDAQ:NVCT) said it holds ex-Greater China rights to NXP200 for BRAF V600 glioma while partner Haisco secured China Breakthrough Therapy for NXP200, and NVCT expects U.S. IND submissions for NXP200 and ciprocopan in Q4 2026 without giving exact filing dates or further milest…